Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions
TWST Stock Forecast
Twist Bioscience stock forecast is as follows: an average price target of $41.20 (represents a -12.25% downside from TWST’s last price of $46.95) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TWST Price Target
The average price target for Twist Bioscience (TWST) is $41.20 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $32.00. This represents a potential -12.25% downside from TWST's last price of $46.95.
TWST Analyst Ratings
According to 7 Wall Street analysts, Twist Bioscience's rating consensus is 'Buy'. The analyst rating breakdown for TWST stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Twist Bioscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Subbu Nambi | Guggenheim | $53.00 | $46.98 | 12.81% | 12.89% |
| May 03, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $40.00 | $32.01 | 24.96% | -14.80% |
| Jan 17, 2024 | Matthew Sykes | Goldman Sachs | $45.00 | $34.84 | 29.16% | -4.15% |
| Feb 05, 2023 | Luke Sergott | Barclays | $32.00 | $25.31 | 26.43% | -31.84% |
| Jan 03, 2023 | - | Evercore ISI | $36.00 | $24.73 | 45.60% | -23.32% |
| Oct 06, 2022 | Luke Sergott | Barclays | $45.00 | $38.51 | 16.85% | -4.15% |
The latest Twist Bioscience stock forecast, released on Jun 05, 2024 by Subbu Nambi from Guggenheim, set a price target of $53.00, which represents a 12.81% increase from the stock price at the time of the forecast ($46.98), and a 12.89% increase from TWST last price ($46.95).
Twist Bioscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $46.00 |
| Last Closing Price | $46.95 | $46.95 | $46.95 |
| Upside/Downside | -100.00% | -100.00% | -2.02% |
In the current month, the average price target of Twist Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Twist Bioscience's last price of $46.95. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Jun 28, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 13, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 04, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 04, 2024 | Guggenheim | - | Buy | Initialise |
| May 06, 2024 | Scotiabank | Outperform | Outperform | Hold |
| May 03, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| May 03, 2024 | William Blair | Outperform | Outperform | Hold |
| May 03, 2024 | Barclays | Overweight | Overweight | Hold |
| Jan 17, 2024 | Goldman Sachs | Neutral | Buy | Upgrade |
Twist Bioscience's last stock rating was published by Scotiabank on Aug 06, 2024. The company gave TWST a "Outperform" rating, the same as its previous rate.
Twist Bioscience Financial Forecast
Twist Bioscience Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $71.50M | $66.95M | $63.74M | $60.18M | $54.24M | $57.31M | - | $48.13M | $42.02M | $37.95M | $35.02M | $31.20M | $28.16M | $32.43M | $21.21M | $19.30M | $17.16M | $15.74M | $13.60M | $13.56M |
| Avg Forecast | $310.50M | $311.00M | $310.00M | $98.08M | $96.54M | $91.13M | $85.17M | $82.54M | $77.40M | $70.70M | $67.59M | $63.35M | $60.62M | $56.64M | $54.41M | $56.90M | $52.06M | $45.26M | $38.63M | $36.60M | $32.42M | $28.32M | $26.10M | $22.95M | $14.18M | $18.28M | $16.22M | $14.05M | $12.77M | $12.05M |
| High Forecast | $315.79M | $316.30M | $315.28M | $99.75M | $98.18M | $92.68M | $86.62M | $82.99M | $78.72M | $71.91M | $68.74M | $63.74M | $61.65M | $57.61M | $55.34M | $57.86M | $52.06M | $46.76M | $39.92M | $37.82M | $33.50M | $29.27M | $26.97M | $23.72M | $14.65M | $18.89M | $16.76M | $14.51M | $13.20M | $12.45M |
| Low Forecast | $294.64M | $295.11M | $294.16M | $93.07M | $91.60M | $86.47M | $80.82M | $81.97M | $73.45M | $67.09M | $64.13M | $62.90M | $57.52M | $53.75M | $51.63M | $53.99M | $52.06M | $44.61M | $38.08M | $36.08M | $31.96M | $27.92M | $25.73M | $22.63M | $13.97M | $18.02M | $15.99M | $13.85M | $12.59M | $11.87M |
| # Analysts | 3 | 4 | 5 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.06% | 1.05% | 1.06% | 1.00% | 1.01% | - | 1.06% | 1.09% | 1.04% | 1.08% | 1.10% | 1.08% | 1.41% | 1.50% | 1.06% | 1.06% | 1.12% | 1.06% | 1.13% |
Twist Bioscience's average Quarter revenue forecast for Mar 24 based on 4 analysts is $70.70M, with a low forecast of $67.09M, and a high forecast of $71.91M. TWST's average Quarter revenue forecast represents a -1.11% decrease compared to the company's last Quarter revenue of $71.50M (Dec 23).
Twist Bioscience EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-46.98M | $-42.97M | $-44.68M | $-59.67M | $-45.88M | $-56.58M | - | $-62.83M | $-52.79M | $-38.39M | $-35.02M | $-35.30M | $2.15M | $-22.02M | $-26.28M | $-29.93M | $-53.85M | $-29.29M | $-25.96M | $-23.95M |
| Avg Forecast | $-297.35M | $-297.83M | $-296.87M | $-93.92M | $-92.45M | $-87.27M | $-81.56M | $-79.05M | $-74.13M | $-76.41M | $-64.73M | $-60.67M | $-58.05M | $-69.46M | $-52.11M | $-39.55M | $-49.86M | $-63.15M | $-60.26M | $-35.96M | $-32.26M | $-34.84M | $2.21M | $-27.06M | $-28.44M | $-25.94M | $-28.43M | $-13.45M | $-22.79M | $-24.93M |
| High Forecast | $-282.16M | $-282.61M | $-281.70M | $-89.13M | $-87.72M | $-82.81M | $-77.39M | $-78.50M | $-70.34M | $-61.13M | $-61.42M | $-60.24M | $-55.09M | $-55.57M | $-49.44M | $-31.64M | $-49.86M | $-50.52M | $-48.21M | $-28.77M | $-25.81M | $-27.87M | $2.65M | $-21.65M | $-22.75M | $-20.75M | $-22.74M | $-13.26M | $-18.23M | $-19.95M |
| Low Forecast | $-302.41M | $-302.90M | $-301.93M | $-95.52M | $-94.02M | $-88.75M | $-82.95M | $-79.48M | $-75.39M | $-91.69M | $-65.83M | $-61.04M | $-59.04M | $-83.35M | $-52.99M | $-47.46M | $-49.86M | $-75.77M | $-72.32M | $-43.15M | $-38.71M | $-41.81M | $1.77M | $-32.47M | $-34.13M | $-31.13M | $-34.11M | $-13.90M | $-27.35M | $-29.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.71% | 0.77% | 0.86% | 0.88% | 1.43% | - | 1.00% | 0.88% | 1.07% | 1.09% | 1.01% | 0.97% | 0.81% | 0.92% | 1.15% | 1.89% | 2.18% | 1.14% | 0.96% |
4 analysts predict TWST's average Quarter EBITDA for Mar 21 to be $-34.84M, with a high of $-27.87M and a low of $-41.81M. This is -1720.35% lower than Twist Bioscience's previous annual EBITDA (Dec 20) of $2.15M.
Twist Bioscience Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-43.01M | $-46.24M | $-57.40M | $-59.16M | $-41.82M | $-51.12M | - | $-60.67M | $-45.56M | $-41.24M | $-40.04M | $-37.92M | $-32.81K | $-24.32M | $-28.21M | $-31.77M | $-55.64M | $-31.18M | $-27.92M | $-25.93M |
| Avg Forecast | - | - | $-40.60M | $-31.65M | $-31.96M | $-36.29M | $-37.82M | $-40.48M | $-44.42M | $-82.01M | $-45.16M | $-53.43M | $-65.40M | $-74.56M | $-65.91M | $-42.49M | $-74.57M | $-67.78M | $-52.01M | $-38.63M | $-36.88M | $-37.43M | $-33.69K | $-29.88M | $-30.53M | $-27.53M | $-29.37M | $-48.01M | $-24.51M | $-27.00M |
| High Forecast | - | - | $-37.91M | $-29.54M | $-29.83M | $-33.88M | $-35.31M | $-39.93M | $-41.47M | $-65.61M | $-42.16M | $-46.46M | $-61.06M | $-59.64M | $-61.54M | $-34.00M | $-74.57M | $-54.22M | $-41.61M | $-30.91M | $-29.50M | $-29.94M | $-26.95K | $-23.90M | $-24.42M | $-22.03M | $-23.50M | $-47.12M | $-19.61M | $-21.60M |
| Low Forecast | - | - | $-41.50M | $-32.35M | $-32.67M | $-37.09M | $-38.65M | $-41.04M | $-45.40M | $-98.41M | $-46.16M | $-72.59M | $-66.85M | $-89.47M | $-67.37M | $-50.99M | $-74.57M | $-81.33M | $-62.41M | $-46.36M | $-44.25M | $-44.91M | $-40.43K | $-35.85M | $-36.63M | $-33.04M | $-35.25M | $-50.09M | $-29.41M | $-32.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 0.87% | 0.88% | 0.79% | 0.63% | 1.20% | - | 0.90% | 0.88% | 1.07% | 1.09% | 1.01% | 0.97% | 0.81% | 0.92% | 1.15% | 1.89% | 0.65% | 1.14% | 0.96% |
Twist Bioscience's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TWST's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Twist Bioscience SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $52.84M | $47.39M | $46.06M | $53.97M | $42.32M | $54.16M | - | $54.00M | $51.10M | $38.24M | $34.48M | $34.39M | $46.95M | $27.18M | $22.49M | $27.19M | $26.41M | $24.42M | $21.32M | $19.12M |
| Avg Forecast | $339.48M | $340.02M | $338.93M | $107.23M | $105.55M | $99.63M | $93.11M | $90.25M | $84.63M | $77.30M | $73.90M | $69.26M | $66.28M | $61.93M | $59.49M | $39.40M | $56.92M | $49.48M | $42.24M | $35.82M | $31.76M | $30.97M | $28.54M | $25.09M | $15.50M | $19.99M | $13.94M | $15.36M | $13.96M | $13.17M |
| High Forecast | $345.26M | $345.81M | $344.70M | $109.06M | $107.34M | $101.33M | $94.70M | $90.74M | $86.07M | $78.62M | $75.15M | $69.69M | $67.40M | $62.98M | $60.50M | $47.29M | $56.92M | $51.13M | $43.64M | $42.99M | $38.11M | $32.00M | $29.49M | $25.93M | $16.01M | $20.65M | $16.73M | $15.87M | $14.43M | $13.61M |
| Low Forecast | $322.13M | $322.65M | $321.61M | $101.75M | $100.15M | $94.54M | $88.36M | $89.62M | $80.30M | $73.35M | $70.12M | $68.77M | $62.89M | $58.76M | $56.45M | $31.52M | $56.92M | $48.78M | $41.64M | $28.66M | $25.40M | $30.53M | $28.13M | $24.74M | $15.28M | $19.70M | $11.15M | $15.14M | $13.77M | $12.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.68% | 0.69% | 0.87% | 0.71% | 1.37% | - | 1.09% | 1.21% | 1.07% | 1.09% | 1.11% | 1.65% | 1.08% | 1.45% | 1.36% | 1.89% | 1.59% | 1.53% | 1.45% |
Twist Bioscience's average Quarter SG&A projection for Mar 24 is $77.30M, based on 4 Wall Street analysts, with a range of $73.35M to $78.62M. The forecast indicates a 46.29% rise compared to TWST last annual SG&A of $52.84M (Dec 23).
Twist Bioscience EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.75 | $-0.81 | $-1.01 | $-1.04 | $-0.74 | $-0.91 | - | $-1.13 | $-0.91 | $-0.84 | $-0.82 | $-0.78 | $-0.00 | $-0.54 | $-0.67 | $-0.85 | $-1.69 | $-0.96 | $-0.92 | $-0.93 |
| Avg Forecast | - | - | $-0.70 | $-0.54 | $-0.55 | $-0.62 | $-0.65 | $-0.70 | $-0.76 | $-0.82 | $-0.78 | $-0.92 | $-1.12 | $-1.13 | $-1.13 | $-1.25 | $-1.29 | $-1.23 | $-1.06 | $-0.80 | $-0.75 | $-0.76 | $-0.70 | $-0.69 | $-0.70 | $-0.76 | $-1.09 | $-0.83 | $-0.82 | $-0.86 |
| High Forecast | - | - | $-0.65 | $-0.51 | $-0.51 | $-0.58 | $-0.61 | $-0.69 | $-0.71 | $-0.76 | $-0.73 | $-0.80 | $-1.05 | $-1.05 | $-1.06 | $-1.17 | $-1.29 | $-1.21 | $-1.04 | $-0.79 | $-0.73 | $-0.75 | $-0.69 | $-0.68 | $-0.69 | $-0.74 | $-1.07 | $-0.82 | $-0.80 | $-0.85 |
| Low Forecast | - | - | $-0.71 | $-0.56 | $-0.56 | $-0.64 | $-0.66 | $-0.71 | $-0.78 | $-0.83 | $-0.79 | $-1.25 | $-1.15 | $-1.15 | $-1.16 | $-1.28 | $-1.29 | $-1.29 | $-1.11 | $-0.84 | $-0.78 | $-0.80 | $-0.73 | $-0.72 | $-0.73 | $-0.79 | $-1.14 | $-0.87 | $-0.85 | $-0.90 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.88% | 0.90% | 0.92% | 0.65% | 0.73% | - | 0.92% | 0.86% | 1.05% | 1.10% | 1.02% | 0.00% | 0.78% | 0.95% | 1.13% | 1.54% | 1.15% | 1.13% | 1.08% |
According to undefined Wall Street analysts, Twist Bioscience's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TWST previous annual EPS of $NaN (undefined).
Twist Bioscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GH | Guardant Health | $26.79 | $57.27 | 113.77% | Buy |
| ILMN | Illumina | $129.18 | $200.82 | 55.46% | Buy |
| EXAS | Exact Sciences | $65.54 | $96.87 | 47.80% | Buy |
| PSNL | Personalis | $5.69 | $7.75 | 36.20% | Hold |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| DHR | Danaher | $274.25 | $313.59 | 14.34% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| TMO | Thermo Fisher Scientific | $611.17 | $646.05 | 5.71% | Buy |
| A | Agilent | $137.31 | $144.90 | 5.53% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| WAT | Waters | $325.86 | $325.00 | -0.26% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.35% | Hold |
| NTRA | Natera | $126.51 | $114.38 | -9.59% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
TWST Forecast FAQ
Is Twist Bioscience a good buy?
Yes, according to 7 Wall Street analysts, Twist Bioscience (TWST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of TWST's total ratings.
What is TWST's price target?
Twist Bioscience (TWST) average price target is $41.2 with a range of $32 to $53, implying a -12.25% from its last price of $46.95. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Twist Bioscience stock go up soon?
According to Wall Street analysts' prediction for TWST stock, the company can go down by -12.25% (from the last price of $46.95 to the average price target of $41.2), up by 12.89% based on the highest stock price target, and down by -31.84% based on the lowest stock price target.
Can Twist Bioscience stock reach $70?
TWST's average twelve months analyst stock price target of $41.2 does not support the claim that Twist Bioscience can reach $70 in the near future.
What are Twist Bioscience's analysts' financial forecasts?
Twist Bioscience's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $370.91M (high $377.23M, low $351.96M), average EBITDA is $-355M (high $-337M, low $-361M), average net income is $-138M (high $-129M, low $-141M), average SG&A $405.52M (high $412.43M, low $384.8M), and average EPS is $-2.368 (high $-2.211, low $-2.421). TWST's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $931.5M (high $947.36M, low $883.91M), average EBITDA is $-892M (high $-846M, low $-907M), average net income is $-40.603M (high $-37.906M, low $-41.502M), average SG&A $1.02B (high $1.04B, low $966.39M), and average EPS is $-0.698 (high $-0.652, low $-0.714).
Did the TWST's actual financial results beat the analysts' financial forecasts?
Based on Twist Bioscience's last annual report (Sep 2023), the company's revenue was $245.11M, beating the average analysts forecast of $235.02M by 4.29%. Apple's EBITDA was $-193M, missing the average prediction of $-240M by -19.59%. The company's net income was $-205M, missing the average estimation of $-259M by -21.09%. Apple's SG&A was $189.74M, missing the average forecast of $256.96M by -26.16%. Lastly, the company's EPS was $-3.6, missing the average prediction of $-4.303 by -16.34%. In terms of the last quarterly report (Dec 2023), Twist Bioscience's revenue was $71.5M, beating the average analysts' forecast of $67.59M by 5.78%. The company's EBITDA was $-46.977M, missing the average prediction of $-64.726M by -27.42%. Twist Bioscience's net income was $-43.008M, missing the average estimation of $-45.159M by -4.76%. The company's SG&A was $52.84M, missing the average forecast of $73.9M by -28.49%. Lastly, the company's EPS was $-0.75, missing the average prediction of $-0.777 by -3.43%